Barclays
TLIS

Barclays’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Barclays’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-229
Closed -$5K – 5334
2022
Q1 		$5K Buy
+229
New +$7.93K ﹤0.01% 4704

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays's TLIS Position: Q2 2022 in Review

Barclays sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q2 2022, closing a stake of 229 shares — an estimated $5K sold.

Barclays first reported a position in TLIS in Q1 2022 and held it in 1 quarter. The position peaked at $5K in Q1 2022. 35 funds tracked by Wall St. Rank hold TLIS as of Q2 2022.

  • Barclays reported no remaining Talis Biomedical Corporation Common Stock position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 229 Talis Biomedical Corporation Common Stock shares in Q2 2022, an estimated $5K.
  • Barclays first reported a position in Talis Biomedical Corporation Common Stock in Q1 2022 and held it in 1 quarter.
  • Barclays's Talis Biomedical Corporation Common Stock position peaked at $5K in Q1 2022.
  • 35 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.